» Articles » PMID: 18382889

Senile Systemic Amyloidosis Affects 25% of the Very Aged and Associates with Genetic Variation in Alpha2-macroglobulin and Tau: a Population-based Autopsy Study

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2008 Apr 3
PMID 18382889
Citations 214
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Senile systemic amyloidosis (SSA) is characterized by deposition of wild-type transthyretin (TTR)-based amyloid in parenchymal organs in elderly individuals. Previously, no population-based studies have been performed on SSA.

Methods: Here we have studied the prevalence and risk factors for SSA in a Finnish autopsied population aged 85 or over, as part of the population-based Vantaa 85+ Autopsy Study (n = 256). The diagnosis of SSA was based on histological examination of myocardial samples stained with Congo red and anti-TTR immunohistochemistry. The genotype frequencies of 20 polymorphisms in 9 genes in subjects with and without SSA were compared.

Results: The prevalence of SSA was 25%. SSA was associated with age, myocardial infarctions, the G/G (Val/Val) genotype of the exon 24 polymorphism in the alpha2-macroglobulin (alpha2M), and the H2 haplotype of the tau gene (P-values 0.002, 0.004, 0.042, and 0.016).

Conclusion: This population-based study shows that SSA is very common in old individuals, affecting one-quarter of people aged over 85 years. Myocardial infarctions and variation in the genes for alpha2M and tau may be associated with SSA.

Citing Articles

Autopsy rates and diagnostic errors in a Swiss community hospital: a ten-year retrospective analysis.

Hagen C, Eriksson U, Schmid K, Flury R, Bode P Virchows Arch. 2025; .

PMID: 40038125 DOI: 10.1007/s00428-025-04060-2.


Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.

Debonnaire P, Dujardin K, Verheyen N, Pouleur A, Droogmans S, Claeys M Eur Heart J. 2025; 46(11):1057-1070.

PMID: 40036202 PMC: 11905754. DOI: 10.1093/eurheartj/ehae923.


International Validation of Echocardiographic AI Amyloid Detection Algorithm.

Duffy G, Oikonomou E, Hourmozdi J, Usuku H, Patel J, Stern L medRxiv. 2025; .

PMID: 39763545 PMC: 11702730. DOI: 10.1101/2024.12.14.24319049.


Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.

Hellenbart E, Ipema H, Rodriguez-Ziccardi M, Krishna H, DiDomenico R Pharmacotherapy. 2024; 45(2):124-144.

PMID: 39714070 PMC: 11823349. DOI: 10.1002/phar.4639.


Amyloids and the Heart: An Update.

Triposkiadis F, Briasoulis A, Xanthopoulos A J Clin Med. 2024; 13(23).

PMID: 39685666 PMC: 11642274. DOI: 10.3390/jcm13237210.